TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Duration of chemotherapy-induced oral mucositis (OM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Summed ocular inflammation score of 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol urge after priming dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance to sedative effects of alcohol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance to lightheaded effects of alcohol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: binary angiographic restenosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: decreased levels of stress biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CMJ flight time: contraction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isometric midthigh-pull relative peak force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement for the presence of radiological contraindications to thrombolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median percent improvement in average pain Numerical Rating Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dilation and evacuation procedure difficulty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initial dilation measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain, fever, and chills incidence
Endpoint domain: Adverse events/effects
Primary endpoint: N1-P1 RADs of R1 and R2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incontinence score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean maximum resting anal sphincter pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective improvement in fecal continence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Induced astigmatism (Naeser)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Keratometric cylinder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induced cylinder (Jaffe)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hetero-dimer PCSK9 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sortilin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychosomatic conditions postoperatively
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Systolic and diastolic function of the left ventricle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ejection fraction postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: BMD values at lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMD values at femoral neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine cross linked N‐telopeptides of type I collagen (NTX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first dose of morphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: depressive symptoms increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intravoxel incoherent motion imaging parameters (D, D*, f values)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Clinically significant improvement in BFRBs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: low-output syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of intestinal obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Wrist flexor MAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: WMFT quality of movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Hand function domain of the SIS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rates of early clopidogrel administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Regular physical activities (caloric expenditure per week)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EC50 of alfentanil for laryngoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: EC50 of alfentanil for intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: EC50 of propofol for regaining consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: work-related stress management
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Immunogenicity of rMenB and rMenB+OMVNW
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reactogenicity of rMenB and rMenB+OMVNW
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of olanzapine compared to other antipsychotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospitalization resource use due to switching antipsychotics
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Crisis services resource use due to switching antipsychotics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: decision making regarding care plans
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Bioequivalence of pediatric formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of major bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: Pulmonary embolism development
Endpoint domain: Adverse events/effects
Primary endpoint: Abstinence rates at week 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GLP-1 level increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Residential mobility rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Nasopharyngeal excretion volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alkaline phosphatase (ALP) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Aspartate aminotransferase (AST) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: immunologic status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: infectious status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in cockroach allergen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: H. pylori-negative test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: failed inductions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: satisfaction with inductions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: General satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Communication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: general psychopathology scale increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall catheter survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician's diagnosis of allergic manifestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Study time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cumulative incidence of CMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean plasma clearance for β2‐microglobulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean plasma clearance for myoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean plasma clearance for IL‐6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CV risk score at M30 visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pre-stent thrombus burden (TB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to Completion (TTC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Curvature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of steps taken
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Home discharge rate
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Decrease in sedentary behavior (SB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatigue recovery rate
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Total number of follow-up days lost to hospitalization, dialysis, or death
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Long-term death for all causes
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of households visited by community health workers
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mortality due to myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Pain pressure threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: association between syndemic risk and unprotected sex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average weight gain per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weekly increments in head circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weekly increments in length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global severity score for erythema, plaque elevation and scaling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Increase in oxygen uptake at ventilatory threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Regression of coronary artery disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean energy expended in leisure time physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective relaxation ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: depressive rumination
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Quantity of oral ulcers
Endpoint domain: Adverse events/effects
Primary endpoint: knowledge and attitude of exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Self-reported use of drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of contraceptive use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Three-month survival
Endpoint domain: Mortality/survival
Primary endpoint: Glasgow Outcome Scale score of 4 or 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Mean serum S100 protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Norepinephrine appearance rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PA2024-specific CTL activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mental skill use
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: cognitive stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: laparoscopic skill improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of ASA's antithrombocyte effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Negative symptoms measured by the Scale for the Assessment of Negative Symptoms (SANS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative symptoms measured by the Brief Psychiatric Rating Scale (BPRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative symptoms measured by the Subjective Deficit Syndrome Scale total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean tube survival
Endpoint domain: Mortality/survival
Primary endpoint: Tube failure rate
Endpoint domain: Adverse events/effects
Primary endpoint: deficits in intentional behavior and in memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: lowering of emotional state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: language and speech problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total daily symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reported functional impairment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: LVAD speed changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Heart failure medication changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: abstinence at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HDL-cholesterol plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fasting insulin plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cardiovascular autonomic regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recurrence of HCC
Endpoint domain: Mortality/survival
Primary endpoint: coronary mortality
Endpoint domain: Mortality/survival
Primary endpoint: coronary morbidity
Endpoint domain: Mortality/survival
Primary endpoint: SDQ scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pressure Pain Threshold (PPT) at the forearm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of hyperprolactinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Perceived fairness of the compensation amount
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: postural control improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of syringing attempts needed per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CCAT scoring improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: object-naming accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thromboembolic events (ischemic stroke, TIA, systemic thromboembolism)
Endpoint domain: Mortality/survival
Primary endpoint: Total hemorrhagic events
Endpoint domain: Adverse events/effects
Primary endpoint: mean number of heroin-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lichenification at week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hypoxemia (SpO2 < 90%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of hypoxemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean lowest SpO2 value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of FSH and LH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum levels of progesterone and estradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: HOMA-IR levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Subperiosteal fluid depth of 4 mm or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Constipation symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SPARCC MRI spinal inflammation index performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for postoperative allogenic blood transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean level of sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen desaturation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient preference for sedation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: motor vehicle crash involvement rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10-year DR rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: HCO3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in pigmentation and uneven tone/erythema scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Wrinkle score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Treatment-related pain or adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom from Survival (FFS)
Endpoint domain: Mortality/survival
Primary endpoint: Late toxicities (esophageal and laryngeal)
Endpoint domain: Adverse events/effects
Primary endpoint: Satisfaction with access to care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Home healthcare costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improved mood outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment engagement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: decrease in the number of arrhythmia episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ventilatory limitation on exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: PaCO2 increase at peak exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peak rate-pressure product
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Exercise-induced ST shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of upper gastrointestinal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of asthma exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: incidence of persistent postcesarean pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain scores of epigastric and global abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder criteria
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mucosal concentration of glutamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Composite endpoint of death, myocardial infarction, target-lesion revascularization, and stroke
Endpoint domain: Mortality/survival
Primary endpoint: Odds of receiving any B-CPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Odds of receiving DA-CPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune response levels to each antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pneumococcal anticapsular immunoglobulin G concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean pharmacodynamic tissue sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean improvement in CRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of any CMV event
Endpoint domain: Adverse events/effects
Primary endpoint: Resting blood antioxidant capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post exercise antioxidant capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes